Hormonal
Incretin receptor agonists (GLP-1RA, dual/triple agonists) and SGLT2 inhibitors reduce the risk of progression to type 2 diabetes and improve cardiovascular outcomes in patients with prediabetes, primarily through weight loss and reduction of visceral ectopic fat.
If you have prediabetes along with obesity, heart failure, or kidney disease, your doctor may consider newer medications like GLP-1 agonists (e.g., semaglutide) or SGLT2 inhibitors. These drugs help with weight loss and reduce cardiovascular risk. They are not yet first-line for all prediabetes patients due to cost and lack of formal indications, but they can be very effective for high-risk individuals.
Reductions in the rate of conversion of prediabetes to diabetes (or increases in the proportion regressing to normoglycemia) have been observed within randomized trials in overweight or obese populations that involved treatment with incretin agonists, including semaglutide (GLP-1RA), liraglutide (GLP-1RA), tirzepatide (dual GLP-1/GIPRA), and retatrutide (triple GLP-1/GIP/glucagon RA). Reduction of visceral ectopic fat appears to be a key mechanism underlying these effects.
Why this rating
Supported by RCTs and systematic reviews, but formal indications for prediabetes are not yet established for all agents.
Source
Intervening Early in the Cardiovascular-Kidney-Metabolic Syndrome: Expert Recommendations from the United Arab Emirates on the Management of Prediabetes
Salah Abusnana et al. · Vascular Health and Risk Management · 2026
DOI 10.2147/vhrm.s579970
More from this paper
- Intensive lifestyle interventions (diet, physical activity, weight management) reduce the risk of progression from prediabetes to type 2 diabetes by 42-58% and improve long-term cardiovascular outcomes.Strong
- Metformin reduces the risk of progression from prediabetes to type 2 diabetes by 31% and is recommended for specific high-risk subgroups (age 25-59, BMI ≥35, FPG ≥6.1 mmol/L, or history of gestational diabetes).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →